The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Open accessAbstract
Programmed death-1 (PD-1) receptor, an inhibitory costimulatory molecule found on activated T cells, has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. We investigated the role of this pathway in the development of autoimmune diabetes. PD-1 or PD-L1 but not PD-L2 blockade rapidly precipitated diabetes in prediabetic female nonobese diabetic (NOD) mice regardless of age (from 1 to 10-wk-old), although it was most pronounced in the older mice. By contrast, cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) blockade induced disease only in neonates. Male NOD mice also developed diabetes after PD-1–PD-L1 pathway blockade, but NOR mice, congenic to NOD but resistant to the development of diabetes, did not. Insulitis scores were significantly higher and frequency of interferon γ–producing GAD-reactive splenocytes was increased after PD-1–PD-L1 pathway blockade compared with controls. Interestingly, PD-L1 but not PD-L2 was found to be expressed on inflamed islets of NOD mice. These data demonstrate a central role for PD-1–PD-L1 interaction in the regulation of induction and progression of autoimmune diabetes in the NOD mouse and provide the rationale to develop new therapies to target this costimulatory pathway in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“This might be of significance in diabetes where in the context of inflamed islets, autoreactive CD8 T cells would be inactivated after encounter with MHC class I on parenchymal cells coexpressing PD-L1 (5, 25).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Self-citationAnti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off
Parijs, L. V., & Abbas, A. K. (1998) · Science · doi:10.1126/science.280.5361.243 · Cited by 965
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
Self-citationCarreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664
Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., & Bluestone, J. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1145 · Cited by 583
Salama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., Azuma, M., Yagita, H., Sayegh, M. H., & Khoury, S. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022119 · Cited by 506
Self-citationYu, L., Robles, D. T., Abiru, N., Kaur, P., Rewers, M., Kelemen, K., & Eisenbarth, G. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556697 · Cited by 450
Wong, F. S., Visintin, I., Wen, L., Flavell, R. A., & Janeway, C. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.67 · Cited by 346
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
Lühder, F., Höglund, P., Allison, J. P., Benoist, C., & Mathis, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.427 · Cited by 290
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells
Yoon, J.-W., Yoon, C.-S., Lim, H.-W., Huang, Q. Q., Kang, Y., Pyun, K. H., Hirasawa, K., Sherwin, R. S., & Jun, H.-S. (1999) · Science · doi:10.1126/science.284.5417.1183 · Cited by 247
Programmed Death-1 Targeting Can Promote Allograft Survival
Özkaynak, E., Wang, L., Goodearl, A., McDonald, K., Qin, S., O’Keefe, T., Duong, T., Smith, T., Gutierrez-Ramos, J.-C., Rottman, J. B., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6546 · Cited by 243
Miyazaki, A., Hanafusa, T., Yamada, K., Miyagawa, J., Fujino-Kurihara, H., Nakajima, H., Nonaka, K., & Tarui, S. (1985) · PubMed Central · Cited by 235
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Autoimmune islet damage mediated by insulin-specific T cells
Crawford, M. L., Daniel, D., Wegmann, D. R., Yang, H., & Gill, R. G. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(96)00457-5 · Cited by 14
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Metadata
- Authors
- Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., Auchincloss, H., & Sayegh, M. H.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-07-07
- Volume
- 198
- Issue
- 1
- Pages
- 63-69
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2158840473
- Cited by
- 814
- References
- 30
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.